Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Elicio Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Elicio Therapeutics, Inc.’s stock price such as:

• Elicio Therapeutics, Inc.’s current stock price and volume
• Why Elicio Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ELTX from analysts
• ELTX’s stock price momentum as measured by its relative strength

About Elicio Therapeutics, Inc. (ELTX)

Before we jump into Elicio Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Want to learn more about Elicio Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Elicio Therapeutics, Inc..

Elicio Therapeutics, Inc.’s Stock Price as of Market Close

As of June 15, 2026, 4:00 PM, CST, Elicio Therapeutics, Inc.’s stock price was $4.080.

Elicio Therapeutics, Inc. is down 72.53% from its previous closing price of $14.850.

During the last market session, Elicio Therapeutics, Inc.’s stock traded between $3.620 and $4.800. Currently, there are approximately 18.21 million shares outstanding for Elicio Therapeutics, Inc..

Elicio Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Elicio Therapeutics, Inc. Stock Price History

Elicio Therapeutics, Inc.’s (ELTX) price is currently down 64.34% so far this month.

During the month of June, Elicio Therapeutics, Inc.’s stock price has reached a high of $16.000 and a low of $3.620.

Over the last year, Elicio Therapeutics, Inc. has hit prices as high as $16.000 and as low as $3.620. Year to date, Elicio Therapeutics, Inc.’s stock is down 48.74%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Elicio Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of June 15, 2026,, no analysts have changed their rating of Elicio Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Elicio Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Elicio Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Elicio Therapeutics, Inc. (ELTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Elicio Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 15, 2026, Elicio Therapeutics, Inc. has a weighted four-quarter relative price strength of -18.10%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Elicio Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Elicio Therapeutics, Inc. Stock Price: Bottom Line

As of June 15, 2026, Elicio Therapeutics, Inc.’s stock price is $4.080, which is down 72.53% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Elicio Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.